RhIGF-1/rhIGFBP-3 ( DrugBank: rhIGFBP-3 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 195 | Noonan syndrome | 1 |
195. Noonan syndrome
Clinical trials : 25 / Drugs : 23 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00351221 (ClinicalTrials.gov) | May 2006 | 11/7/2006 | Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome | A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome | Noonan Syndrome | Drug: rhIGF-1/rhIGFBP-3 | Insmed Incorporated | NULL | Terminated | 2 Years | 16 Years | Both | 24 | Phase 2 | United States |